A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance

por Haahr, Hanne, Heise, Tim
Publicado 2014

Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences

por Haahr, Hanne, Heise, Tim
Publicado 2019

A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use

por Haahr, Hanne, Fita, Edmond G., Heise, Tim
Publicado 2016

Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose‐lowering effects

por Haahr, Hanne, Sasaki, Tomio, Bardtrum, Lars, Ikushima, Ippei
Publicado 2016

Fast‐acting insulin aspart in Japanese patients with type 1 diabetes: Faster onset, higher early exposure and greater early glucose‐lowering effect relative to insulin aspart

por Shiramoto, Masanari, Nishida, Tomoyuki, Hansen, Ann Kathrine, Haahr, Hanne
Publicado 2017

Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients

por Ikushima, Ippei, Kaku, Kohei, Hirao, Koichi, Bardtrum, Lars, Haahr, Hanne
Publicado 2015

Pharmacological properties of faster‐acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, doub...

por Heise, Tim, Zijlstra, Eric, Nosek, Leszek, Rikte, Tord, Haahr, Hanne
Publicado 2016

A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes

por Heise, Tim, Pieber, Thomas R., Danne, Thomas, Erichsen, Lars, Haahr, Hanne
Publicado 2017

Insulin Degludec: Pharmacokinetic Properties in Subjects with Hepatic Impairment

por Kupčová, Viera, Arold, Gerhard, Roepstorff, Carsten, Højbjerre, Malene, Klim, Søren, Haahr, Hanne
Publicado 2013

Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus

por Heise, Tim, Nosek, Leszek, Roepstorff, Carsten, Chenji, Suresh, Klein, Oliver, Haahr, Hanne
Publicado 2014

Insulin Degludec: Pharmacokinetics in Patients with Renal Impairment

por Kiss, István, Arold, Gerhard, Roepstorff, Carsten, Bøttcher, Susanne Gammelgaard, Klim, Søren, Haahr, Hanne
Publicado 2013

The Distinct Prandial and Basal Pharmacodynamics of IDegAsp Observed in Younger Adults Are Preserved in Elderly Subjects with Type 1 Diabetes

por Brunner, Martina, Pieber, Thomas, Korsatko, Stefan, Kojzar, Harald, Svendsen, Anne Louise, Haahr, Hanne
Publicado 2015

Insulin degludec: Lower day‐to‐day and within‐day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes

por Heise, Tim, Nørskov, Marianne, Nosek, Leszek, Kaplan, Kadriye, Famulla, Susanne, Haahr, Hanne L.
Publicado 2017

A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus

por Heise, Tim, Hövelmann, Ulrike, Zijlstra, Eric, Stender-Petersen, Kirstine, Jacobsen, Jacob Bonde, Haahr, Hanne
Publicado 2016

Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions

por Hövelmann, Ulrike, Heise, Tim, Nosek, Leszek, Sassenfeld, Bettina, Thomsen, Karen Margrete Due, Haahr, Hanne
Publicado 2017

Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover stu...

por Koehler, Gerd, Heller, Simon, Korsatko, Stefan, Roepstorff, Carsten, Rasmussen, Søren, Haahr, Hanne, Pieber, Thomas R.
Publicado 2013

Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjec...

por Haahr, Hanne, Pieber, Thomas R., Mathieu, Chantal, Gondolf, Theis, Shiramoto, Masanari, Erichsen, Lars, Heise, Tim
Publicado 2018

Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy

por Heise, Tim, Heinemann, Lutz, Hövelmann, Ulrike, Brauns, Bianca, Nosek, Leszek, Haahr, Hanne L., Olsen, Klaus J.
Publicado 2009

Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellit...

por Heise, Tim, Stender-Petersen, Kirstine, Hövelmann, Ulrike, Jacobsen, Jacob Bonde, Nosek, Leszek, Zijlstra, Eric, Haahr, Hanne
Publicado 2016

Fast‐acting insulin aspart in people with type 2 diabetes: Earlier onset and greater initial exposure and glucose‐lowering effect compared with insulin aspart

por Pieber, Thomas R., Svehlikova, Eva, Brunner, Martina, Halberg, Inge B., Due Thomsen, Karen Margrete, Haahr, Hanne
Publicado 2019